The Company’s lead clinical candidates, SRX246 and SRX251, are first-in-class, CNS-penetrating, high affinity, high selectivity V1a receptor antagonists that are orally bioavailable. These compounds represent a potential breakthrough approach for the treatment of stress-related affective disorders, including intermittent explosive disorder, neuropsychiatric symptoms in neurodegenerative diseases such as Huntington’s Disease and Alzheimer’s Disease, and PTSD. In the U.S. alone, these disorders affect more than 40 million people.
SRX246 is in a Phase II clinical trial for the treatment of Intermittent Explosive Disorder that will be completed in Q2 2016. Both SRX246 and SRX251 reduce measures of stress, fear, aggression, depression, and anxiety in preclinical models, including neuroimaging investigations. A translational human Experimental Medicine fMRI study confirmed robust CNS effects after oral dosing in circuits that are dysregulated in stress-related disorders. This unique combination of properties demonstrates exceptional promise for vasopressin antagonists as a novel approach to treating disorders of stress, mood, and behavior. Phase II clinical trials for the treatment Huntington’s Disease patients with irritability and for the treatment of PTSD will launch in Q2 2016. The development of these compounds has been supported by the National Institutes of Health through multiple SBIR grants, the National Toxicology Evaluation Program, the RAID Program, the NINDS NeuroNext program; through a grant from the Dept. of Defense; and private venture capital.